Rapport Therapeutics, Inc. 8-K Summary
Business Context and Reporting Period
This Form 8-K reports on the 2025 Annual Meeting of Stockholders held by Rapport Therapeutics, Inc. on June 17, 2025. The record date for the meeting was April 21, 2025, with 36,497,555 shares of common stock outstanding and entitled to vote.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and voting results.
Material Changes and Voting Results
Stockholders voted on two proposals, both of which were approved:
- Proposal 1 (Election of Directors): Stockholders elected Reid Huber, Ph.D., John Maraganore, Ph.D., and Wendy B. Young, Ph.D. as Class I directors to serve until the 2028 annual meeting.
- Proposal 2 (Auditor Ratification): Stockholders ratified the appointment of PricewaterhouseCoopers LLP (PwC) as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items.
Investor Verification Checklist
- Verify the terms of office for the newly elected Class I directors (Reid Huber, John Maraganore, Wendy B. Young).
- Confirm the engagement of PwC as the independent auditor for the fiscal year ending December 31, 2025.
- Review the Definitive Proxy Statement filed on April 24, 2025, for detailed background on the director nominees and auditor selection.